A Cochrane review of seven RCTs (494 participants) finds low- to very low-certainty evidence that select medical therapies — notably recombinant human nerve growth factor — may improve corneal re-epithelialization in neurotrophic keratopathy; evidence on vision, sensitivity, and surgical options remains inconclusive.